536 research outputs found
Hot topics on vertebral osteomyelitis from the International Society of Antimicrobial Chemotherapy
Copyright © 2019. Published by Elsevier B.V.Peer reviewedPostprin
Proposal of serovars 17 and 18 of Actinobacillus pleuropneumoniae based on serological and genotypic analysis
The aim of this study was to investigate isolates of Actinobacillus pleuropneumoniae previously designated serologically either as NT or as âK2:07â, which did not produce serovar-specific amplicons in PCR assays.
We used whole genome sequencing to identify the capsule (CPS) loci of six previously designated biovar 1 non-typable (NT) and two biovar 1 âK2:O7â isolates of A. pleuropneumoniae from Denmark, as well as a recent biovar 2 NT isolate from Canada. All of the NT isolates have the same six-gene type I CPS locus, sharing common cpsABC genes with serovars 2, 3, 6, 7, 8, 9, 11 and 13. The two âK2:O7â isolates contain a unique three-gene type II CPS locus, having a cpsA gene similar to that of serovars 1, 4, 12, 14 and 15. The previously NT isolates share the same O-antigen genes, found between erpA and rpsU, as serovars 3, 6, 8, and 15. Whereas the âK2:O7â isolates, have the same O-antigen genes as serovar 7, which likely contributed to their previous mis-identification. All of the NT and âK2:O7â isolates have only the genes required for production of ApxII (apxIICA structural genes, and apxIBD export genes).
Rabbit polyclonal antisera raised against representative isolates with these new CPS loci demonstrated distinct reactivity compared to the 16 known serovars. The serological and genomic results indicate that the isolates constitute new serovars 17 (previously NT) and 18 (previously âK2:O7â). Primers designed for amplification of specific serovar 17 and 18 sequences for molecular diagnostics will facilitate epidemiological tracking of these two new serovars of A. pleuropneumoniae
Reactivation of Clostridium tertium bone infection 30 years after the Iran-Iraq war
Clostridium tertium could be responsible forlate metal fragment bone and joint infection.LateC. tertium metal fragment bone and joint infections requires a multidisciplinary management. Late C. tertium metal fragment bone and joint infections requires metal extraction and prolonged antimicrobial therapy for healin
Co-infection with HIV and HCV in 229 children and young adults living in Europe
OBJECTIVE: To characterise children, adolescents and young adults infected with HIV/HCV vertically or before age 18 years and living in Europe regarding mode of acquisition, HCV genotype, clinical status and treatment. DESIGN: Retrospective, cross-sectional study using pooled data from 11 European paediatric HIV cohorts METHODS:: Patients agedâ>â18 months andââ40âIU/L at their last test. Of 97 patients with transient elastography, 12 had resultsâ>â9 kPa; this was associated with duration of HCV infection (pâ=â0.033), but not with CD4 count, ART use or gender in univariable analysis. Of 17 subjects with liver biopsies, 6 had bridging fibrosis and one cirrhosis. Twenty-five (11%) had been treated successfully for HCV. CONCLUSIONS: The high proportion of patients with progressive liver disease underscores the need for close monitoring and earlier and more effective HCV treatment
Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: observational analyses within the ARREST trial
Adjunctive rifampicin did not reduce failure/recurrence/death as a composite endpoint in the ARREST trial of Staphylococcus aureus bacteraemia, but did reduce recurrences. We investigated clinically-defined 14-day treatment failure, and recurrence and S. aureus-attributed/unattributed mortality by 12-weeks to further define their predictor
Resumen ejecutivo de la DeclaraciĂłn de consenso del Grupo de Estudio de la InfecciĂłn en el Trasplante (GESITRA) de la Sociedad Española de Enfermedades Infecciosas y MicrobiologĂa ClĂnica (SEIMC) y la OrganizaciĂłn Nacional de Trasplantes (ONT) sobre los criterios de selecciĂłn de donantes de Ăłrganos sĂłlidos en relaciĂłn con las enfermedades infecciosas
The immunosuppressive treatment that recipients receive from a solid organ transplantation hinders the defensive response to infection. Its transmission from the donor can cause dysfunction or loss of the graft and even death of the recipient if proper preventive measures are not established. This potential risk should be thoroughly evaluated to minimise the risk of infection transmission from donor to recipient, especially with organ transplantation from donors with infections, without increasing graft dysfunction and morbidity and mortality in the recipient. This document aims to review current knowledge about infection screening in potential donors and offer clinical and microbiological recommendations about the use of organs from donors with infection based on available scientific evidence.This work was supported by GESITRA/SEIMC, ONT andâPlan Nacional de I+D+Iâ and Instituto de Salud Carlos III(Fondo de Investigaciones Sanitarias 12/02269 and ProyectoIntegrado de Excelencia 13/00045), SubdirecciĂłn General de Redesy Centros de Investigacion Cooperativa, Spanish Ministry of Econ-omy and Competitiveness, Spanish Network for Research inInfectious Diseases (REIPI RD16/0016), co-financed by the Euro-pean Development Regional Fund A way to achieve Europe
Post-COVID-19 condition and persisting symptoms in English schoolchildren: repeated surveys to March 2022
BACKGROUND: Both post-COVID-19 condition (long COVID) and the presence of persisting symptoms that do not meet formal definitions of post-COVID-19-condition may adversely affect quality of life and function. However, their prevalence among children and young people in England is unclear. METHODS: We used data from repeated surveys in a large cohort of English schoolchildren from the COVID-19 Schools Infection Survey (SIS) for the school year 2021/22 to describe the weighted prevalence of post-COVID-19-condition and compare persisting symptoms between individuals with a positive SARS-CoV-2 test and those with neither a positive test history nor suspected infection. RESULTS: Among 7797 children from 173 schools, 1.8% of primary school pupils (aged 4 to 11Â years), 4.5% of secondary school pupils in years 7-11 (aged 11 to 16Â years) and 6.9% of those in years 12-13 (aged 16 to 18Â years) met a definition of post-COVID-19 condition in March 2022. Specific persisting symptoms such as anxiety or difficulty concentrating were frequently reported regardless of prior infection status and increased with age: 48.0% of primary school pupils, 52.9% of secondary school pupils in years 7-11 and 79.5% in years 12-13 reporting at least one symptom lasting more than 12Â weeks. Persisting loss of smell and taste, cardiovascular and some systemic symptoms were more frequently reported by those with a previous positive test. CONCLUSIONS: We showed that ongoing symptoms were frequently reported by English schoolchildren regardless of SARS-CoV-2 test results and some specific symptoms such as loss of smell and taste were more prevalent in those with a positive test history. Our study emphasises the wide-ranging impacts of the COVID-19 pandemic on the health and wellbeing of children and young people
- âŠ